Price$36.49+5.64 (+18.28%)
2026-05-212026-08-25
News · 26 weeks74+25%
2026-03-012026-08-23
Mix3290d
- Insider20(63%)
- SEC Filings6(19%)
- Earnings4(13%)
- Other2(6%)
Latest news
25 items- INSIDERCFO Pulik Richard covered exercise/tax liability with 5,749 shares, decreasing direct ownership by 2% to 271,810 units (SEC Form 4) (withholding obligation)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & Immunovant CEO Venker Eric covered exercise/tax liability with 13,909 shares, decreasing direct ownership by 0.86% to 1,599,154 units (SEC Form 4) to cover withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & CIO Sukhatme Mayukh sold $12,360,813 worth of shares (335,174 units at $36.88) and exercised 335,174 shares at a strike of $3.85 (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & CIO Sukhatme Mayukh exercised 664,826 shares at a strike of $3.85 and sold $24,160,402 worth of shares (664,826 units at $36.34) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Roivant Sciences Ltd.SCHEDULE 13G/A - Roivant Sciences Ltd. (0001635088) (Subject)
- SECSEC Form 10-Q filed by Roivant Sciences Ltd.10-Q - Roivant Sciences Ltd. (0001635088) (Filer)
- SECRoivant Sciences Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Roivant Sciences Ltd. (0001635088) (Filer)
- PRRoivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business UpdateCommercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU) expected in the second half of calendar year 2026First patients enrolled in the Phase 3 study of brepocitinib in cutaneous sarcoidosis (CS), with topline data expected in calendar year 2028; enrollment in Part 1 of the Phase 2b/3 study in lichen planopilaris (LPP) is progressing wellIMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) topline data expected in the second half of calendar year 2026; all clinical development timelines remain on track for IMVT-1402Mosliciguat
- PRImmunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren’s disease (SjD) and cutaneous lupus erythematosus (CLE)Current cash balance provides runway to the potential launch of IMVT-1402 in GDRoivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate update
- PRPriovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)CS is a highly morbid, chronic, and disfiguring condition with no approved therapiesBrepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase 2 BEACON) and has received FDA Breakthrough Therapy Designation for CSGlobal Phase 3 study (BEACON+) is underway, evaluating brepocitinib 45 mg once daily against placebo in 140 patients across approximately 70 sites globally; BEACON+ topline data expected in calendar year 2028Brepocitinib’s development program now includes four indications with ongoing or successfully completed registrational trials: dermatomyositis (DM), non-infectious uveitis (NIU), lichen planopilaris (LPP), and CS; pote
- INSIDERPresident & Immunovant CEO Venker Eric exercised 200,000 shares at a strike of $3.85 and sold $6,990,000 worth of shares (200,000 units at $34.95) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- SECSEC Form DEFA14A filed by Roivant Sciences Ltd.DEFA14A - Roivant Sciences Ltd. (0001635088) (Filer)
- SECSEC Form DEF 14A filed by Roivant Sciences Ltd.DEF 14A - Roivant Sciences Ltd. (0001635088) (Filer)
- PRImmunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August 6, 2026 before the market opens. Roivant Sciences Ltd. (ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant. To access the Roivant (NASDAQ:ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "News & Events" in the Investors section of the Immunovant website at https://www.immunov
- PRRoivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (NASDAQ:ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026, to report its financial results for the first quarter ended June 30, 2026, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under "Events & Presentations" in the Investors section of the Roivant website at https://investor.roivant.com/news-events/events. The archived webcast will be available on Roivant’s website after the conference call. About
- INSIDERDirector Epperly Melissa B, was granted 543 shares, increasing direct ownership by 3% to 17,017 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Oren Ilan was granted 775 shares, increasing direct ownership by 0.64% to 121,004 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Momtazee James C was granted 405 shares, increasing direct ownership by 0.37% to 109,810 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERCEO Gline Matthew covered exercise/tax liability with 76,171 shares, decreasing direct ownership by 0.46% to 16,659,945 units (SEC Form 4) (for withholding tax)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Fitzgerald Meghan exercised 10,000 shares at a strike of $8.80 and sold $349,000 worth of shares (10,000 units at $34.90) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident and Vant Chair Torti Frank covered exercise/tax liability with 40,310 shares, decreasing direct ownership by 0.30% to 13,536,202 units (SEC Form 4) to cover withholding tax4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERPresident & CIO Sukhatme Mayukh covered exercise/tax liability with 46,878 shares, decreasing direct ownership by 0.25% to 18,630,739 units (SEC Form 4) to satisfy tax liability4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Epperly Melissa B, sold $610,252 worth of shares (17,750 units at $34.38) and exercised 17,750 shares at a strike of $4.46 (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Manchester Keith S sold $56,444,076 worth of shares (1,638,163 units at $34.46), decreasing direct ownership by 10% to 1,748,403 units (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
- INSIDERDirector Gold Daniel Allen sold $49,354,076 worth of shares (1,438,163 units at $34.32) (SEC Form 4)4 - Roivant Sciences Ltd. (0001635088) (Issuer)
ROIV FAQ
6 questionsWhat does Roivant Sciences Ltd. do?
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.Where does ROIV stock trade?
Roivant Sciences Ltd. (ROIV) is listed on NASDAQ.What sector and industry is ROIV in?
Roivant Sciences Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ROIV?
Roivant Sciences Ltd. has had 8 recent analyst actions on file. The most recent action was from Bernstein: Outperform with a $3500.00 price target on 2026-03-20. Recent price targets range from $1050.00 to $3500.00.What companies are similar to ROIV?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ROIV side-by-side with any of them on Quantisnow.How can I track ROIV on Quantisnow?
Quantisnow aggregates Roivant Sciences Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ROIV to receive live email and push alerts on every new disclosure.